Please select the option that best describes you:
What factors drive you to prioritize treatments that inhibit T cells vs B cell depletion when choosing therapies for patients with refractory SLE?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
Answer from: at Community Practice
Other than for immune cytopenias that are likely primarily autoAb mediated it is difficult to know the relative extent to which T cell vs humoral immunity effects lupus disease activity. As such, the main driver for me to target T-cell activation currently would be organ complications not known to b...
Sign In or Register to read more